1. Home
  2. CASH vs IDYA Comparison

CASH vs IDYA Comparison

Compare CASH & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CASH
  • IDYA
  • Stock Information
  • Founded
  • CASH 1954
  • IDYA 2015
  • Country
  • CASH United States
  • IDYA United States
  • Employees
  • CASH N/A
  • IDYA N/A
  • Industry
  • CASH Major Banks
  • IDYA Biotechnology: Pharmaceutical Preparations
  • Sector
  • CASH Finance
  • IDYA Health Care
  • Exchange
  • CASH Nasdaq
  • IDYA Nasdaq
  • Market Cap
  • CASH 1.8B
  • IDYA 1.9B
  • IPO Year
  • CASH N/A
  • IDYA 2019
  • Fundamental
  • Price
  • CASH $80.20
  • IDYA $24.50
  • Analyst Decision
  • CASH Buy
  • IDYA Strong Buy
  • Analyst Count
  • CASH 2
  • IDYA 13
  • Target Price
  • CASH $91.00
  • IDYA $50.82
  • AVG Volume (30 Days)
  • CASH 203.0K
  • IDYA 1.0M
  • Earning Date
  • CASH 07-28-2025
  • IDYA 08-05-2025
  • Dividend Yield
  • CASH 0.25%
  • IDYA N/A
  • EPS Growth
  • CASH 10.71
  • IDYA N/A
  • EPS
  • CASH 7.36
  • IDYA N/A
  • Revenue
  • CASH $731,383,000.00
  • IDYA $7,000,000.00
  • Revenue This Year
  • CASH $14.15
  • IDYA $115.83
  • Revenue Next Year
  • CASH $5.99
  • IDYA $252.50
  • P/E Ratio
  • CASH $10.90
  • IDYA N/A
  • Revenue Growth
  • CASH 6.51
  • IDYA N/A
  • 52 Week Low
  • CASH $60.42
  • IDYA $13.45
  • 52 Week High
  • CASH $86.00
  • IDYA $44.42
  • Technical
  • Relative Strength Index (RSI)
  • CASH 48.87
  • IDYA 65.66
  • Support Level
  • CASH $79.77
  • IDYA $21.33
  • Resistance Level
  • CASH $84.75
  • IDYA $25.54
  • Average True Range (ATR)
  • CASH 2.00
  • IDYA 1.00
  • MACD
  • CASH -0.42
  • IDYA 0.21
  • Stochastic Oscillator
  • CASH 8.50
  • IDYA 75.93

About CASH Pathward Financial Inc.

Pathward Financial Inc is a unitary savings and loan holding company. It's a wholly owned full-service banking subsidiary of Meta Financial, is both a community-oriented financial institution offering a variety of financial services to meet the needs of the communities it serves, and a payments company providing services on a nationwide basis. It operates through three reportable segments: Consumer: The Consumer segment includes the Partner Solutions business line, which collaborates with partners to navigate payment and lending needs; Commercial: The Commercial segment includes the Company's Commercial Finance business line, which helps businesses access funds needed to launch, operate, and grow; and Corporate Services. The majority of the revenue is generated from Consumer segment.

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

Share on Social Networks: